These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7959407)

  • 21. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum.
    Endo T; Minami M; Kitamura N; Teramoto Y; Ogawa T; Nemoto M; Hamaue N; Hirafuji M; Yasuda E; Blower PR
    Res Commun Mol Pathol Pharmacol; 1999; 104(2):145-55. PubMed ID: 10634307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential Roles of 5-HT
    Satiamurthy R; Yaakob NS; Shah NM; Azmi N; Omar MS
    Curr Mol Med; 2023; 23(4):341-349. PubMed ID: 35549869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined blockade of 5-HT3- and 5-HT4-serotonin receptors inhibits colonic functions in conscious rats and mice.
    Nagakura Y; Kontoh A; Tokita K; Tomoi M; Shimomura K; Kadowaki M
    J Pharmacol Exp Ther; 1997 Apr; 281(1):284-90. PubMed ID: 9103508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy.
    Karim F; Roerig SC; Saphier D
    Biochem Pharmacol; 1996 Sep; 52(5):685-92. PubMed ID: 8765466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of GK-128 [2-[(2-methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one monohydrochloride hemihydrate], a selective 5-hydroxytryptamine3 receptor antagonist, on colonic function in rats.
    Ito C; Isobe Y; Kawamura R; Kiuchi Y; Tsuchida K; Higuchi S
    J Pharmacol Exp Ther; 1997 Jan; 280(1):67-72. PubMed ID: 8996183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
    Wolf H
    Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures.
    Mongeau R; De Montigny C; Blier P
    Eur J Pharmacol; 1994 May; 256(3):269-79. PubMed ID: 8045271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
    Gan TJ
    CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives.
    Ohta M; Suzuki T; Furuya T; Kurihara H; Tokunaga T; Miyata K; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1996 Sep; 44(9):1707-16. PubMed ID: 8855365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential influence of two serotonin 5-HT3 receptor antagonists on spinal serotonin-induced analgesia in rats.
    Bardin L; Jourdan D; Alloui A; Lavarenne J; Eschalier A
    Brain Res; 1997 Aug; 765(2):267-72. PubMed ID: 9313899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action.
    Freeman AJ; Cunningham KT; Tyers MB
    Anticancer Drugs; 1992 Apr; 3(2):79-85. PubMed ID: 1525396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.